Unveiling the Demographics and Clinical Characteristics of Diabetic Neuropathy: Findings From the National Health Insurance Service, 2012-2017.

IF 3.7 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Pub Date : 2026-05-01 DOI:10.1111/1753-0407.70196

Su Jin Jeong, Sun Keun Kim, Chong Hwa Kim

{"title":"Unveiling the Demographics and Clinical Characteristics of Diabetic Neuropathy: Findings From the National Health Insurance Service, 2012-2017.","authors":"Su Jin Jeong, Sun Keun Kim, Chong Hwa Kim","doi":"10.1111/1753-0407.70196","DOIUrl":null,"url":null,"abstract":"Background: Diabetic neuropathy (DN) is the most common chronic complication of Type 2 diabetes mellitus (T2DM), with reported prevalence ranging from 23% to 54.5%. This study evaluated the prevalence, clinical characteristics, and treatments of DN using Korean National Health Insurance Service (NHIS) data from 2012 to 2017.Methods: We analyzed NHIS sample data for 8.7 million individuals stratified by age, sex, eligibility, and income. DN was defined using ICD-10 codes (E10.4-E14.4, G59.0, G63.2, G99.0) and concurrent prescriptions for diabetes and DN. Annual DN prevalence among diabetes patients was calculated, and treatment patterns and patient characteristics were compared between those with and without DN.Results: DN prevalence declined from 23.4% in 2012 to 21.5% in 2017. About half of DN patients received pharmacologic treatment-mainly monotherapy (up to 82%), followed by dual (15%) and triple therapy (3%). The most prescribed drugs were α-lipoic acid (52.1%-55.0%), anticonvulsants (30.4%-34.5%), tricyclic antidepressants, SNRIs, and γ-linolenic acid. DN patients were generally older, more often female, and had more comorbidities such as hypertension, dyslipidemia, cardiovascular disease, diabetic foot, and amputations. They were also more likely to use insulin or multiple oral agents.Conclusion: About one-quarter of patients with T2DM had DN, and half received treatment, mostly α-lipoic acid monotherapy. DN patients tended to be older and had multiple comorbidities, resulting in higher hospitalization rates.","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 5","pages":"e70196"},"PeriodicalIF":3.7000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13126423/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1753-0407.70196","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Diabetic neuropathy (DN) is the most common chronic complication of Type 2 diabetes mellitus (T2DM), with reported prevalence ranging from 23% to 54.5%. This study evaluated the prevalence, clinical characteristics, and treatments of DN using Korean National Health Insurance Service (NHIS) data from 2012 to 2017.

Methods: We analyzed NHIS sample data for 8.7 million individuals stratified by age, sex, eligibility, and income. DN was defined using ICD-10 codes (E10.4-E14.4, G59.0, G63.2, G99.0) and concurrent prescriptions for diabetes and DN. Annual DN prevalence among diabetes patients was calculated, and treatment patterns and patient characteristics were compared between those with and without DN.

Results: DN prevalence declined from 23.4% in 2012 to 21.5% in 2017. About half of DN patients received pharmacologic treatment-mainly monotherapy (up to 82%), followed by dual (15%) and triple therapy (3%). The most prescribed drugs were α-lipoic acid (52.1%-55.0%), anticonvulsants (30.4%-34.5%), tricyclic antidepressants, SNRIs, and γ-linolenic acid. DN patients were generally older, more often female, and had more comorbidities such as hypertension, dyslipidemia, cardiovascular disease, diabetic foot, and amputations. They were also more likely to use insulin or multiple oral agents.

Conclusion: About one-quarter of patients with T2DM had DN, and half received treatment, mostly α-lipoic acid monotherapy. DN patients tended to be older and had multiple comorbidities, resulting in higher hospitalization rates.

查看原文本刊更多论文

揭示糖尿病神经病变的人口统计学和临床特征：来自2012-2017年国民健康保险服务的调查结果。

背景：糖尿病性神经病变（DN）是2型糖尿病（T2DM）最常见的慢性并发症，据报道患病率从23%到54.5%不等。本研究利用2012年至2017年韩国国民健康保险服务（NHIS）的数据评估了DN的患病率、临床特征和治疗方法。方法：我们分析了870万名按年龄、性别、资格和收入分层的NHIS样本数据。使用ICD-10代码（E10.4-E14.4, G59.0, G63.2, G99.0）和糖尿病和DN并发处方定义DN。计算糖尿病患者年度DN患病率，比较糖尿病患者和非糖尿病患者的治疗模式和患者特征。结果：DN患病率从2012年的23.4%下降到2017年的21.5%。大约一半的DN患者接受了药物治疗，主要是单药治疗（高达82%），其次是双药治疗（15%）和三联治疗（3%）。处方药物最多的是α-硫辛酸（52.1% ~ 55.0%）、抗惊厥药（30.4% ~ 34.5%）、三环抗抑郁药、SNRIs、γ-亚麻酸。DN患者一般年龄较大，多为女性，并有较多的合并症，如高血压、血脂异常、心血管疾病、糖尿病足、截肢等。他们也更有可能使用胰岛素或多种口服药物。结论：约1 / 4的T2DM患者有DN，其中一半接受了治疗，以α-硫辛酸单药治疗为主。DN患者往往年龄较大，有多种合并症，住院率较高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

2.20%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Diabetes (JDB) devotes itself to diabetes research, therapeutics, and education. It aims to involve researchers and practitioners in a dialogue between East and West via all aspects of epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. The Editorial team is international with a unique mix of Asian and Western participation. The Editors welcome submissions in form of original research articles, images, novel case reports and correspondence, and will solicit reviews, point-counterpoint, commentaries, editorials, news highlights, and educational content.